Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
MDVN > SEC Filings for MDVN > Form 8-K on 31-Mar-2014All Recent SEC Filings

Show all filings for MEDIVATION, INC.

Form 8-K for MEDIVATION, INC.


31-Mar-2014

Change in Directors or Principal Officers


Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 31, 2014, Rick Bierly joined Medivation, Inc. as its new chief financial officer. Mr. Bierly will serve as Medivation's principal financial and accounting officer and will report to David Hung, M.D., president and chief executive officer.

Mr. Bierly, age 58, brings to Medivation over 30 years experience in finance roles at Glaxo-SmithKline, Aventis, Centocor and Johnson & Johnson. Mr. Bierly served as an executive director in Ernst & Young's (EY) Financial Accounting Advisory Services practice for life sciences and other clients from September 2013 to present, where he provided advisory services in connection with Finance function transformations. From 1999 to 2012, he served in several leadership roles at Johnson & Johnson, including vice president, Skillman NJ Shared Financial Services Center, where he was responsible for a shared services center providing financial accounting services to Johnson and Johnson's US-based operating companies. Mr. Bierly also served as vice president and chief financial officer of Centocor and Ortho Biotech, and prior to that served as executive director, finance, following the acquisition of the Centocor biotechnology business by Johnson and Johnson. From 1997 to 1999 he was at Centocor Diagnostics as vice president and chief financial officer and Centocor as executive director, finance. From 1995 to 1997 he served as vice president and treasurer of a Aventis-Hoechst start-up joint venture in the blood plasma business. He also worked in senior financial roles at Aventis (1991 to 1995) and SmithKline Beecham (1981 to 1991). Mr. Bierly began his career in public accounting at EY. He holds a Bachelor of Business Administration degree from Pennsylvania State University and is a CPA in PA and NJ.

Pursuant to an offer letter entered into between Mr. Bierly and Medivation, Mr. Bierly will receive an annual base salary of $458,000, and his annual target bonus will be 60% of base salary. In addition, Mr. Bierly will receive a one-time bonus of $320,000, repayable on a pro rata basis if voluntarily leaves Medivation within two years from the date of employment.

Pursuant to the offer letter Mr. Bierly is also expected to be granted: (1) a stock option to purchase 31,023 shares of Medivation common stock with an exercise price equal to the closing price of a share of Medivation common stock on the date of grant, vesting over four years; and (2) a restricted stock unit to acquire 15,511 shares of Medivation common stock, vesting over three years. In the event of a change of control of Medivation, the vesting of these grants will be accelerated in full.

Mr. Bierly will also participate in Medivation's relocation program, which provides that Mr. Bierly's relocation expenses, subject to specified caps, will be paid for by Medivation, and taxable amounts will be grossed up. Relocation expenses paid are subject to repayment in the event that Mr. Bierly voluntarily leaves Medivation before the second anniversary of his employment start date.

Patrick Machado, Medivation's chief financial officer and chief business officer, has transitioned out of his role as chief financial officer and will retire from Medivation in April 2014.


  Add MDVN to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for MDVN - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.